First-in-Man, Randomised, Double-Blind, Placebo-Controlled, Single Dose Escalation Study of the Novel Compound 4SC-203 in Young Healthy Volunteers
Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Investigation of safety and tolerability of escalating single doses of 4SC-203.
Frank Wagner, PD Dr. med.
Charité Research Organisation GmbH, Berlin, Germany
Germany: Federal Institute for Drugs and Medical Devices